Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
暂无分享,去创建一个
Edwin DeJesus | Anna Wald | S. Trottier | A. Wald | T. Schacker | M. Shahmanesh | T. Warren | E. Dejesus | Terri Warren | Timothy W Schacker | Mohsen Shahmanesh | Sylvie Trottier | Joanne L Hill | Clare A Brennan | C. Brennan | Joanne Hill
[1] L. Corey,et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. , 1998, The Journal of infectious diseases.
[2] T. Schacker,et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials , 2002, International journal of STD & AIDS.
[3] D. Cooper,et al. A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection , 1998 .
[4] Anna Wald,et al. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] N. Flournoy,et al. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. , 1984, Annals of internal medicine.
[6] J. Zeh,et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. , 2002, The Journal of infectious diseases.
[7] W. Bell,et al. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). , 1997, Medicine.
[8] F. Aoki,et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals , 2000 .
[9] B. Everitt,et al. Statistical methods for rates and proportions , 1973 .
[10] H. Balfour,et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. , 1982, The American journal of medicine.
[11] W. Reeves,et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. , 2003, Archives of internal medicine.
[12] J. Zeh,et al. Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial , 1998, Annals of Internal Medicine.
[13] P. Collins,et al. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. , 1986, The Journal of antimicrobial chemotherapy.
[14] G. Darby,et al. Survey of Resistance of Herpes Simplex Virus to Acyclovir in Northwest England , 1998, Antimicrobial Agents and Chemotherapy.
[15] D. Cederberg,et al. Pharmacokinetics of the acyclovir pro‐drug valaciclovir after escalating single‐and multiple‐dose administration to normal volunteers , 1993, Clinical pharmacology and therapeutics.
[16] L. Corey,et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. , 1984, The New England journal of medicine.